B-lymfom dolních končetin, chemoterapie, anti-CD20, radioterapie.
نویسندگان
چکیده
منابع مشابه
Anti-CD20 antibody therapy for B-cell lymphomas.
n engl j med 366;21 nejm.org may 24, 2012 2008 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...
متن کاملPerspectives Am“B”valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis
Accumulating evidence has designated B cells as central players in the pathogenesis of immune diseases. In the late 1990s, anti-CD20 monoclonal antibodies were developed for the treatment of B-cell nonHodgkin lymphomas, offering the opportunity to efficiently deplete the B-cell compartment for therapeutic immunointerventions. Several studies have since established the beneficial effect of this ...
متن کاملAm"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis.
Accumulating evidence has designated B cells as central players in the pathogenesis of immune diseases. In the late 1990s, anti-CD20 monoclonal antibodies were developed for the treatment of B-cell non-Hodgkin lymphomas, offering the opportunity to efficiently deplete the B-cell compartment for therapeutic immunointerventions. Several studies have since established the beneficial effect of this...
متن کاملUnexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab).
This study describes a woman patient suffering from rheumatoid arthritis which was resistant to treatment with the most commonly used DMARDs and anti-TNF alfa drugs, however following the administration of a minimum dose of Rituximab the patient showed a persistent and complete depletion of CD 20 lymphocytes. The dose of Rituximab administered to the patient was halted at 50 mg due to the onset...
متن کاملOfatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dermatologie pro praxi
سال: 2016
ISSN: 1802-2960,1803-5337
DOI: 10.36290/der.2016.045